Abstract
The role and timing of cytoreductive nephrectomy in the immunotherapy era require further investigation. Extrapolation of data from the cytokine era that demonstrated an overall survival benefit of cytoreductive nephrectomy suggest that similar results might emerge from future trials using immunotherapy agents.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have